{"id":"NCT01737398","sponsor":"Ionis Pharmaceuticals, Inc.","briefTitle":"Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy","officialTitle":"A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (NEURO-TTR Study)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2013-03-15","primaryCompletion":"2017-03-03","completion":"2017-11-07","firstPosted":"2012-11-29","resultsPosted":"2019-01-23","lastUpdate":"2019-07-17"},"enrollment":173,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["FAP","Familial Amyloid Polyneuropathy","TTR","Transthyretin","Amyloidosis"],"interventions":[{"type":"DRUG","name":"Inotersen","otherNames":["TEGSEDI","IONIS-TTR Rx","ISIS 420915"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Inotersen","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of inotersen given for 65 weeks in participants with Familial Amyloid Polyneuropathy (FAP).","primaryOutcome":{"measure":"Change From Baseline In The Modified Neuropathy Impairment Score (mNIS) +7 Composite Score at Week 66","timeFrame":"Baseline and Week 66","effectByArm":[{"arm":"Inotersen","deltaMin":4.16,"sd":15.672},{"arm":"Placebo","deltaMin":23.89,"sd":24.19}],"pValues":[{"comp":"OG000 vs OG001","p":"0.00000004"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":13},"locations":{"siteCount":24,"countries":["United States","Argentina","Brazil","France","Germany","Italy","New Zealand","Portugal","Spain","United Kingdom"]},"refs":{"pmids":["29972757","35799473","35766224","34355354","34125267","32833564","32654212","32654156","31853709","30219500","30169969"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":112},"commonTop":["Nausea","Fatigue","Diarrhoea","Injection site erythema","Headache"]}}